Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens.

about

Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens.

Item

http://www.wikidata.org/entity/Q55003928

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Detection of cervical precance ...... preservative fluid specimens.

@en

Detection of cervical precance ...... preservative fluid specimens.

@nl

type

Item

label

Detection of cervical precance ...... preservative fluid specimens.

@en

Detection of cervical precance ...... preservative fluid specimens.

@nl

prefLabel

Detection of cervical precance ...... preservative fluid specimens.

@en

Detection of cervical precance ...... preservative fluid specimens.

@nl

P1476

Detection of cervical precance ...... preservative fluid specimens.

@en

P2093

Alice Lytwyn

http://www.w3.org/2001/XMLSchema#string

Barbara Weinbaum

http://www.w3.org/2001/XMLSchema#string

Brett Kirkconnell

http://www.w3.org/2001/XMLSchema#string

Damon Getman

http://www.w3.org/2001/XMLSchema#string

Dan Jang

http://www.w3.org/2001/XMLSchema#string

Janel Dockter

http://www.w3.org/2001/XMLSchema#string

Jenny Li

http://www.w3.org/2001/XMLSchema#string

Jodi Gilchrist

http://www.w3.org/2001/XMLSchema#string

Laurie Elit

http://www.w3.org/2001/XMLSchema#string

Manuel Arias

http://www.w3.org/2001/XMLSchema#string

P2860

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer

A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4

Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.

Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method.

Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer

Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.

Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.

Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.

Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.

Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.

P304

155-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PVR.2017.04.005

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28720450

http://www.w3.org/2001/XMLSchema#string

P932

5883188

http://www.w3.org/2001/XMLSchema#string